Successful treatment of refractory Langerhans cell histiocytosis by allogeneic peripheral blood stem cell transplantation

Pediatric Transplantation
Chi-Chieh LaiShin-Nan Cheng

Abstract

We describe a six-yr-old boy who exhibited typical signs and symptoms of LCH with EBV-associated hemophagocytic syndrome from the age of 15 months. Multiple courses of conventional chemotherapy achieved only marginal improvement over the ensuring five yr. During this period, this boy experienced recurrent episodes of hemophagocytic syndrome associated with CMV infection. Five yr after the first diagnosis of LCH, the patient was treated with allogeneic PBSCT from his HLA-identical eight-yr-old brother. PBSCT was performed using a TBI-incorporating conditioning regimen comprising TBI, busulfan, and cyclophosphamide. Diabetes insipidus, typically a permanent consequence of LCH, was well controlled by DDAVP therapy. At the time of writing, this boy is alive and well, and had been disease-free for more than two yr after the PBSCT.

References

May 9, 1987·Lancet·J I HenterA Ost
Feb 1, 1994·Current Opinion in Obstetrics & Gynecology·D A Fishman, P E Schwartz
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R H CollinsJ Nemunaitis
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A BrownJ F DiPersio
Mar 23, 2002·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Blaise E FavaraR Maarten Egeler
Mar 24, 2005·Journal of Cellular and Molecular Medicine·Jan JansenLuke P Akard

❮ Previous
Next ❯

Citations

Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia S L MüllerClaudia Pföhler
Feb 2, 2019·Muscle & Nerve·Anne M ConnollyUNKNOWN MDA DMD Clinical Research Network

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.